News & Updates
Filter by Specialty:
Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC
First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.
Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC
08 Jan 2025
Retifanlimab plus chemo improves survival in metastatic NSCLC
The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.
Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
07 Jan 2025
Corticosteroid phobia tied to poor treatment adherence in chronic hand eczema
Topical corticosteroid (TCS) phobia (TOPICOP) commonly exists among patients with chronic hand eczema (CHE) and often leads to poor treatment adherence, suggests a recent study.